IGF-1 and ADMA Levels Are Inversely Correlated in Nondiabetic Ankylosing Spondylitis Patients Undergoing Anti-TNF-Alpha Therapy

Table 2

Partial correlation of plasma IGF-1 and IGFBP-3 with metabolic parameters at baseline, prior to an infliximab infusion, adjusting by age at the time of the study, sex, and classic cardiovascular risk factors (dyslipidemia, smoking, obesity, and hypertension) in 30 nondiabetic patients with ankylosing spondylitis.

Variable	IGF-1		IGFBP-3
	HOMA-IR at time 0*	0.273	0.17	0.052	0.80
QUICKI at time 0*	−0.280	0.16	−0.116	0.56
Resistin at time 0	0.341	0.12	−0.270	0.22
Adiponectin at time 0	−0.215	0.29	0.158	0.44
Leptin at time 0	0.313	0.12	−0.310	0.12
Visfatin at time 0	−0.074	0.72	0.068	0.74
Angpt-2 at time 0	0.080	0.69	0.274	0.17
Apelin at time 0	−0.005	0.98	0.237	0.23
ADMA at time 0	−0.397	0.04	−0.346	0.08
Ghrelin at time 0	−0.175	0.39	−0.327	0.10
Gelsolin at time 0	0.148	0.46	0.180	0.37
OPN at time 0	0.168	0.40	0.004	0.99
RBP-4 at time 0	0.339	0.08	0.053	0.79
OPG at time 0	−0.049	0.81	0.063	0.76
TRAIL at time 0	0.109	0.59	0.122	0.54
IGFBP-3 at time 0	0.163	0.42	—	—
IGF-1 at time 0	—	—	0.163	0.42

At the time of the study.
ADMA: asymmetric dimethylarginine; Angpt-2: angiopoietin-2; HOMA-IR: homeostasis model assessment of insulin resistance; IGF-1: insulin-like growth factor 1; IGFBP-3: insulin-like growth factor binding protein-3; OPG: osteoprotegerin; OPN: osteopontin; QUICKI: quantitative insulin sensitivity check index; RBP-4: retinol binding protein-4; TRAIL: TNF-related apoptosis-inducing ligand. Significant results are highlighted in bold.